Jefferies Group LLC reissued their hold rating on shares of Genomic Health, Inc. (NASDAQ:GHDX) in a research report released on Thursday morning. The firm currently has a $33.00 target price on the medical research company’s stock.

A number of other equities research analysts also recently issued reports on the company. Cowen and Company restated a hold rating and set a $34.00 price objective on shares of Genomic Health in a research report on Friday, September 1st. Zacks Investment Research downgraded Genomic Health from a hold rating to a sell rating in a research report on Tuesday, August 1st. Piper Jaffray Companies restated a hold rating and set a $31.00 price objective on shares of Genomic Health in a research report on Thursday, August 3rd. BidaskClub downgraded Genomic Health from a hold rating to a sell rating in a research report on Friday, August 4th. Finally, Canaccord Genuity decreased their price objective on Genomic Health from $36.00 to $35.00 and set a buy rating on the stock in a research report on Tuesday, August 15th. Two analysts have rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company. Genomic Health currently has an average rating of Hold and an average target price of $32.00.

Shares of Genomic Health (NASDAQ:GHDX) traded up 0.87% during trading on Thursday, hitting $31.27. The stock had a trading volume of 225,418 shares. The stock has a 50 day moving average of $30.93 and a 200 day moving average of $31.60. Genomic Health has a 12 month low of $26.37 and a 12 month high of $33.97. The company’s market cap is $1.08 billion.

Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Genomic Health had a negative net margin of 1.50% and a negative return on equity of 4.33%. The company had revenue of $85.50 million for the quarter, compared to analysts’ expectations of $86.08 million. During the same quarter last year, the company earned ($0.18) earnings per share. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. Equities analysts forecast that Genomic Health will post ($0.01) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Genomic Health, Inc. (GHDX) Given Hold Rating at Jefferies Group LLC” was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/09/15/genomic-health-inc-ghdx-given-hold-rating-at-jefferies-group-llc.html.

In other news, COO G Bradley Cole sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $31.86, for a total transaction of $159,300.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Phillip G. Febbo sold 3,174 shares of the company’s stock in a transaction that occurred on Wednesday, July 19th. The shares were sold at an average price of $33.57, for a total value of $106,551.18. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 42,642 shares of company stock worth $1,354,431. Insiders own 46.20% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Dubuque Bank & Trust Co. grew its stake in Genomic Health by 8.4% in the second quarter. Dubuque Bank & Trust Co. now owns 4,897 shares of the medical research company’s stock worth $159,000 after purchasing an additional 379 shares in the last quarter. Legal & General Group Plc grew its stake in Genomic Health by 48.7% in the first quarter. Legal & General Group Plc now owns 6,222 shares of the medical research company’s stock worth $196,000 after purchasing an additional 2,038 shares in the last quarter. SG Americas Securities LLC grew its stake in Genomic Health by 37.8% in the second quarter. SG Americas Securities LLC now owns 6,122 shares of the medical research company’s stock worth $199,000 after purchasing an additional 1,679 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new position in Genomic Health in the first quarter worth approximately $218,000. Finally, Envestnet Asset Management Inc. grew its stake in Genomic Health by 13.6% in the first quarter. Envestnet Asset Management Inc. now owns 8,282 shares of the medical research company’s stock worth $259,000 after purchasing an additional 993 shares in the last quarter. 88.91% of the stock is currently owned by institutional investors.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.